MAHAMAYA LIFESCIENCES LIMITED
(Formerly Known as Mahamaya Lifesciences Pvt. Ltd.)
369, 370, 370A and 370B, 3rd Floor, Tower B-1,
Spaze ITech Park, Sector-49, Sohna Road,
Gurugram - 122018, Haryana, India
Tel. : +91-124-4301988 / 4101430 / 4371988
E-mail : info@mahamayalifesciences.com
Web. : www.mahamayalifesciences.com
CIN : L24233DL2002PLC115261

Certificate No: IQ-24112602/A

Date: November 13, 2026

To,
The Listing Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001

Scrip Code: 544611

Sub: Disclosure under Regulation 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Outcome of Board meeting held on Friday, 13th November, 2026.

Dear Sir / Madam,

Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we wish to inform you that the Board of Directors of **Mahamaya Lifesciences Limited** at its meeting held today, i.e., November 13, 2026, has, inter-alia, considered and approved the following(s):

Financial Results:

Un-Audited Standalone & Consolidated Financial Results for the half year ended September 30, 2026. In this regard, please find enclosed:

a. Un-Audited Standalone & Consolidated Financial Results of the Company for the half year ended September 30, 2026.

b. Limited Review Report in respect of the Un-Audited Standalone & Consolidated Financial Results of the Company for the half year ended September 30, 2026.

The Meeting of the Board of Directors commenced at 11:45 A.M and concluded at 01:05 P.M

You are requested to kindly take the above on record.

For Mahamaya Lifesciences Limited

Kush Mishra

Digitally signed by Kush Mishra
DN: c=IN, o=Personal, pseudonym=k6p8245790amtzislwgvdx31hrecbjqf, 2.5.4.20=2623889418f9aeffba54aa80bfd56f74ffa17a5ade107e734416f9d294aae8c4, postalCode=110077, st=Delhi, serialNumber=a1145a153c7d819866547a717fe3620984cceefa8918a6e3640d8eceb28780d6, cn=Kush Mishra
Date: 2026.11.13 13:16:56 +05'30'

Kush Mishra
Company Secretary & Compliance officer
M. No: A62001

N NARESH & CO
Chartered Accountants

E. Kumar B.Com., FCA

Independent Auditor's Limited Review Report on the Unaudited Standalone Financial Results for the Half Year Ended September 30, 2026 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to

The Board of Directors
Mahamaya Lifesciences Limited
(formerly known as Mahamaya Lifesciences Private Limited)

We have reviewed the accompanying statement of unaudited standalone financial results of Mahamaya Lifesciences Limited (the "Company") for the half year ended September 30, 2026 (the "Statement"). This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors at its meeting held on November 13, 2026. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **N Naresh and Co.**
Chartered Accountants
Firm Registration no: 0011293S

N. NARESH & CO FRN-011293S Chartered Accountants

CA Kumar E
Partner
Membership Registration Number: 217549
UDIN: 26217549KXFKBZ8642

Place: Chennai
Date:13/11/2026

Mahamaya Lifesciences Limited
(Formerly Known as Mahamaya Lifesciences Private Limited)
CIN: L24233DL2002PLC115261
Unaudited Standalone Statement of Asset and Liabilities for the period ended September 30,2026

(All amounts are in Indian Rupees in Lakhs, except otherwise stated)

Particulars	Half Year Ended September 30,2026 Unaudited	Year Ended March 31,2026 Audited
Equity and liabilities		
Shareholder's fund		
Share Capital	2,340.50	2,340.50
Reserves and Surplus	11,085.95	9,922.29
	13,426.45	**12,262.79**
Non current liabilities		
Long Term Borrowings	656.92	356.80
Long Term Provisions	44.35	44.34
Deferred Tax Liabilities (net)	154.01	120.50
	855.28	**521.64**
Current liabilities		
Short Term Borrowings	11,168.98	8,716.87
Trade Payables		
(A) total outstanding dues of creditors other than micro ente	9,331.71	6,352.79
(B) total outstanding dues of micro enterprises and small en	254.87	91.35
Other Current Liabilities	253.27	587.12
Short Term Provisions	2,371.21	2,563.91
	23,380.05	**18,312.04**
TOTAL	**37,661.78**	**31,096.47**
Assets		
Non current assets		
Property, Plant and Equipment	2,999.22	2,308.32
Capital Work in Progress	331.13	574.35
Intangible Assets- Product Research	1,297.35	1,169.98
Intangible Assets - Pre-operative Exp. New Plant	9.05	27.25
Intangible Assets under development- Product Research	336.64	259.50
Non Current Investments	4.90	4.90
Other Non Current Assets	92.74	44.05
	5,071.03	**4,388.35**
Current assets		
Inventories	15,446.33	14,105.26
Trade Receivables	9,091.87	7,075.99
Cash and Bank Balances	6,332.99	3,939.90
Short Term Loans, Advances and Deposits	1,606.81	1,513.04
Other current assets	112.75	73.93
	32,590.75	**26,708.12**
TOTAL	**37,661.78**	**31,096.47**

For and on behalf of the Board of Directors of
Mahamaya Lifesciences Limited

Krishnamurthy Ganesan
Chairman & Director
DIN - 00270539

Place : Gurugram
Date : 13-11-2026

Mahamaya Lifesciences Limited
(Formerly Known as Mahamaya Lifesciences Private Limited)
CIN: L24233DL2002PLC115261
Statement of Unaudited Standalone Financial Results for the period ended September 30,2026

(All amounts are in Indian Rupees in Lakhs, except otherwise stated)

Particulars	Figures for the Half year ended 30-09-2026	Figures for the Half year ended 31-03-2026	Figures for the Half year ended 30-09-2025	Figures for the year ended 31-03-2026
	Unaudited	Unaudited	Unaudited	Audited
I. Revenue From Operations	21,162.92	16,580.93	16,306.37	32,887.30
II. Other Operating Income	-	8.81	32.52	41.33
III. Other Income	79.78	43.77	30.83	74.60
IV. Total Income (I+II)	**21,242.70**	**16,633.51**	**16,369.72**	**33,003.23**
V. Expenses				
-Purchases of Goods and Other Direct Expenses	19,136.21	14,465.27	17,103.14	31,568.41
-(Increase)/ Decrease in Inventories	(1,341.07)	(919.88)	(3,164.62)	(4,084.50)
-Employee Benefit Expenses	518.67	441.99	387.26	829.25
-Financial Cost	619.09	428.85	385.02	813.87
-Depreciation and Amortization	143.06	114.48	109.76	224.24
-Other Expenses	603.76	852.21	392.10	1,244.31
Total Expenses	**19,679.72**	**15,382.92**	**15,212.66**	**30,595.58**
VI. Prior period Expenses	-	-	**0.44**	**0.44**
VII. Profit Before Tax	**1,562.98**	**1,250.59**	**1,156.62**	**2,407.21**
VIII. Tax Expense				
(1)Current Tax	365.81	329.57	282.31	611.88
(2)Deferred Tax	33.51	32.84	16.99	49.83
(3)Earlier Year Taxes	-	68.66	4.76	73.42
Total Tax Expenses	**399.32**	**431.07**	**304.06**	**735.13**
IX. Profit for the Period	**1,163.67**	**819.52**	**852.56**	**1,672.08**
X. Earnings Per Equity Share				
(1) Basic	4.97	3.50	4.80	8.43
(2) Diluted	4.97	3.50	4.80	8.43

For and on behalf of the Board of Directors of
Mahamaya Lifesciences Limited



Krishnamurthy Ganesan
Chairman & Director
DIN - 00270539

Place : Gurugram
Date : 13-11-2026

Mahamaya Lifesciences Limited
(Formerly Known as Mahamaya Lifesciences Private Limited)
CIN: L24233DL2002PLC115261
Unaudited Standalone Statement of Cash Flow for the period ended September 30,2026

(All amounts are in Indian Rupees in Lakhs, except otherwise stated)

Particulars	Half Year Ended September 30,2026 Unaudited	Year Ended March 31,2026 Audited
A. Cash flow from Operating activities		
Profit before tax	**1,562.98**	**2,407.21**
Adjustments for :		
Depreciation and Amortisation	143.06	224.24
Interest Expense	619.09	813.87
Liabilities written back	(5.89)	-
(Profit)/Loss on sale of PPE	-	0.89
Interest Income	(73.90)	(45.44)
Operating profit before Working Capital changes	**2,245.34**	**3,400.77**
Working Capital changes:		
(Increase)/ decrease in Inventories	(1,341.07)	(4,084.50)
(Increase)/ decrease in Trade Receivables	(2,015.88)	(2,229.70)
(Increase)/decrease in Short-term Loans, Advances and Deposits	(93.77)	(1,101.30)
(Increase)/decrease in Other Current Assets	(115.96)	112.21
(Increase)/decrease in Other Non Current Assets	(2.69)	0.81
(Decrease)/Increase in Trade Payables	3,142.44	937.34
Increase/ (decrease) in Other Current Liabilities	(333.84)	(104.03)
Increase/(decrease) in Provisions	(252.62)	546.82
Cash generated from /(used in) operations	**1,231.95**	**(2,521.58)**
Direct taxes paid (net of refunds received)	(300.00)	(436.15)
Net cash flow from/(used in) Operating activities	**931.95**	**(2,957.73)**
B. Cash flow from Investing activities		
Purchase of Property, Plant and Equipment	(542.62)	(880.83)
Addition to Intangibles	(157.29)	(729.26)
Investment in Fixed deposits	(46.00)	-
Sale of Property, Plant and Equipment	-	10.40
Interest received	73.90	45.44
Net cash flow from/(used in) Investing activities	**(672.01)**	**(1,554.25)**
C. Cash flow from Financing activities		
Interest paid	(619.08)	(813.87)
Fresh issue of Equity Shares	-	563.88
Share Premium	-	5,864.35
Issue Expenses	-	(824.23)
Proceeds from Long term Borrowings	300.12	-
Repayment of Long term Borrowings	-	(259.20)
Proceeds from Short term Borrowings	2,452.11	3,521.46
Repayment of Short term Borrowings	-	-
Net cash flow from/(used in) Financing activities	**2,133.15**	**8,052.39**
Net increase in cash and Cash equivalents (A+B+C)	**2,393.09**	**3,540.41**
Cash and Cash equivalents at the beginning of the year	3,939.90	399.49
Cash and Cash equivalents as at the end of the year	**6,332.99**	**3,939.90**
Net difference in cash and cash equivalent	-	-

For and on behalf of the Board of Directors of
Mahamaya Lifesciences Limited

Krishnamurthy Ganesan
Chairman & Director
DIN - 00270539

Place : Gurugram
Date : 13-11-2026

Notes to Standalone Financial Results

1. The above Unaudited Standalone Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors in their Meeting held on November 13, 2026. The Statutory Auditors of the Company have conducted a "Limited Review" of the above Financial Results for half year ended 30th September, 2026.
2. These financial results have been prepared in accordance with the requirements of Accounting Standards specified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 as amended time to time.
3. The Company has only one reportable Business segment viz. "Agro Chemicals".
4. The demand for Company's products depends on monsoon, pest infestation and crop patterns. Hence there may be variations in the Results from one period to another period.
5. As per MCA notification dated 16th February, 2015 Companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 are exempted from the compulsory requirements of adoption of IND-AS.
6. The Company was listed on the stock exchange on 18th November 2025. In connection with the public issue, equity shares having a face value of Rs. 10 each were issued at a share premium of Rs. 104 per equity share, resulting in an issue price of Rs. 114 per share. The public issue comprised an aggregate of 61,78,800 equity shares, comprising of 56,38,800 equity shares issued through a Fresh Issue and 5,40,000 equity shares offered for sale by the Promoters. The proceeds from the Fresh Issue were received by the Company (Rs. 64,28,23,200), whereas the consideration in respect of the Offer for Sale accrued to the Promoters. The public issue was undertaken in accordance with the provisions of the Companies Act, 2013 and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.
7. The utilisation of IPO proceeds is summarised as under, as certified by the Statutory auditor via certificate dated 3rd November 2026

Sr. No.	Objects of the Issue (as per Prospectus)	Amount Allocated as per Prospectus (₹ crore)	Amount Utilised during the Period (₹ crore)	Unutilised Amount (₹ crore)
1	Purchase of Equipment for Fungicides, Insecticides and Bio fermented formulations	2.98	1.27	1.71
2	Purchase of Equipment for herbicides	0.78	0.22	0.55
3	Funding of capital expenditure towards setting up of new technical manufacturing plant	29.42	3.13	26.28
4	Construction of Warehouse and purchase of machinery	2.53	1.83	0.70
5	Funding of Working capital	18.00	18.00	-
6	General Corporate purpose	8.26	8.26	-
	Total	**61.96**	**32.72**	**29.24**


MAHAMAYA LIFESCIENCES LIMITED

Out of Rs. 29.24 crore of unutilised funds, Rs. 1.72 crore is the balance in the Monitoring Account and the remaining Rs. 27.52 crore has been deposited in Fixed Deposits, being permitted instruments as per the SEBI ICDR Regulations. The breakup of the same is given below:

Breakup of Fixed Deposits:

Date of Deposit	Name of the Bank	Tenure	Amount Deposited (Rs.)
23-Apr-26	DBS	181 days	3,01,00,000.00
23-Apr-26	DBS	182 days	3,01,00,000.00
22-Jun-26	DBS	122 days	3,00,00,000.00
12-May-26	Yes Bank	181 days	7,50,00,000.00
18-May-26	Axis Bank	185 days	5,00,00,000.00
20-Mar-26	DBS	367 days	1,00,00,000.00
13-Aug-26	HDFC	274 days	3,00,00,000.00
22-Sep-26	HDFC	46 days	1,00,00,000.00
22-Sep-26	HDFC	30 days	1,00,00,000.00
	Total		27,52,00,000.00

8. The figures of the corresponding periods have been regrouped/reclassified, wherever necessary to conform to current period classification/presentation.
9. The above unaudited financial results of the Company are available on the Company's website (www.mahamayalifesciences.com) and stock exchanges websites BSE (www.bseindia.com), where the shares of the Company are listed.



N NARESH & CO
Chartered Accountants

E. Kumar B.Com., FCA

Independent Auditor's Limited Review Report on Consolidated Unaudited Half Year Financial Results of Mahamaya Lifesciences Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The board of directors of
MAHAMAYA LIFESCIENCES LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Mahamaya Lifesciences Limited ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the half year ended 30th September 2026 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulations").

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

   Mahamaya Lifesciences Limited – Parent (Holding Company)

   Mahamaya Lifesciences (FZE) – Wholly Owned Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial information of one foreign subsidiary, Mahamaya Lifesciences (FZE), included in the consolidated unaudited financial results, whose interim financial information reflects total assets of Rs. 38.25 lakhs as at 30th September 2026, total revenue for the period is Nil and total net loss after tax of Rs. 8.80 lakhs for the half year ended 30th September 2026, and net cash flows is Nil for the period from 1st April 2026 to 30th September 2026, as considered in the consolidated unaudited financial results. Our conclusion on the Statement is not modified in respect of the above matter.

For N Naresh and Co.
Chartered Accountants
Firm Registration No.: 0011293S





CA Kumar E
Partner
Membership No.: 217549
UDIN: 26217549EVVYQA9494

Place: Chennai
Date: 13/11/2026

Mahamaya Lifesciences Limited

(Formerly Known as Mahamaya Lifesciences Private Limited)

CIN: L24233DL2002PLC115261

Unaudited Consolidated Statement of Asset and Liabilities for the period ended September 30,2026

(All amounts are in Indian Rupees in Lakhs, except otherwise stated)

Particulars	Half Year Ended September 30,2026 Unaudited	Year Ended March 31,2026 Audited
Equity and liabilities		
Shareholder's fund		
Share Capital	2,340.50	2,340.50
Reserves and Surplus	11,006.73	9,852.49
	13,347.23	**12,192.99**
Non current liabilities		
Long Term Borrowings	656.92	356.80
Long Term Provisions	44.35	44.35
Deferred Tax Liabilities (net)	154.01	120.50
	855.28	**521.65**
Current liabilities		
Short Term Borrowings	11,168.98	8,716.87
Trade Payables		
(A) total outstanding dues of creditors other than micro enterprises	9,331.71	6,352.79
(B) total outstanding dues of micro enterprises and small enterprises	254.87	91.35
Other Current Liabilities	253.28	587.12
Short Term Provisions	2,372.58	2,565.25
	23,381.42	**18,313.38**
TOTAL	**37,583.92**	**31,028.02**
Assets		
Non current assets		
Property, Plant and Equipment	2,999.22	2,308.32
Capital Work in Progress	331.13	574.35
Intangible Assets- Product Research	1,297.35	1,169.98
Intangible Assets - Pre-operative Exp. New Plant	9.05	27.25
Intangible Assets under development- Product Research	336.64	259.50
Other Non Current Assets	92.74	44.05
	5,066.13	**4,383.45**
Current assets		
Inventories	15,446.33	14,105.26
Trade Receivables	9,091.87	7,075.99
Cash and Bank Balances	6,332.99	3,939.90
Short Term Loans, Advances and Deposits	1,533.85	1,449.49
Other current assets	112.75	73.93
	32,517.79	**26,644.57**
TOTAL	**37,583.92**	**31,028.02**

For and on behalf of the Board of Directors of
Mahamaya Lifesciences Limited

MAHAMAYA LIFESCIENCES LIMITED

Krishnamurthy Ganesan
Chairman & Director
DIN - 00270539

Place : Gurugram
Date : 13-11-2026

Mahamaya Lifesciences Limited

(Formerly Known as Mahamaya Lifesciences Private Limited)

CIN: L24233DL2002PLC115261

Statement of Unaudited Consolidated Financial Results for the period ended September 30,2026

(All amounts are in Indian Rupees in Lakhs, except otherwise stated)

Particulars	Figures for the Half year ended 30-09-2026	Figures for the Half year ended 31-03-2026	Figures for the Half year ended 30-09-2025	Figures for the year ended 31-03-2026
	Unaudited	Unaudited	Unaudited	Audited
I. Revenue From Operations	21,162.92	16,580.93	16,306.37	32,887.30
II. Other Operating Income	-	8.81	32.52	41.33
III. Other Income	79.78	43.77	30.83	74.60
IV. Total Income (I+II)	**21,242.70**	**16,633.51**	**16,369.72**	**33,003.23**
V. Expenses				
-Purchases of Goods and Other Direct Expenses	19,136.21	14,465.27	17,103.14	31,568.41
-(Increase)/ Decrease in Inventories	(1,341.07)	(919.88)	(3,164.62)	(4,084.50)
-Employee Benefit Expenses	518.67	441.99	387.26	829.25
-Financial Cost	619.09	428.84	385.02	813.88
-Depreciation and Amortization	143.06	114.47	109.76	224.24
-Other Expenses	612.56	856.28	407.47	1,263.75
Total Expenses	**19,688.52**	**15,386.97**	**15,228.04**	**30,615.03**
VI. Prior period Expenses	-	-	**0.44**	**0.44**
VII. Profit Before Tax	**1,554.18**	**1,246.54**	**1,141.24**	**2,387.76**
VIII. Tax Expense				
(1)Current Tax	365.81	329.57	282.31	611.88
(2)Deferred Tax	33.50	32.85	16.99	49.83
(3)Earlier Year Taxes	-	68.66	5.06	73.73
Total Tax Expenses	**399.31**	**431.08**	**304.36**	**735.44**
IX. Profit for the Period	**1,154.87**	**815.46**	**836.88**	**1,652.32**
X. Earnings Per Equity Share				
(1) Basic	4.93	3.72	4.71	8.33
(2) Diluted	4.93	3.72	4.71	8.33

For and on behalf of the Board of Directors of
Mahamaya Lifesciences Limited

MAHAMAYA LIFESCIENCES LIMITED

Krishnamurthy Ganesan
Chairman & Director
DIN - 00270539

Place : Gurugram
Date : 13-11-2026

Mahamaya Lifesciences Limited

(Formerly Known as Mahamaya Lifesciences Private Limited)

CIN: L24233DL2002PLC115261

Unaudited Consolidated Statement of Cash Flow for the period ended September 30,2026

(All amounts are in Indian Rupees in Lakhs, except otherwise stated)

Particulars	Half Year Ended September 30,2026 Unaudited	Year Ended March 31,2026 Audited
A. Cash flow from Operating activities		
Profit before tax	**1,554.18**	**2,387.77**
Adjustments for :		
Depreciation and Amortisation	143.06	224.24
Interest Expense	619.09	813.87
Liabilities written back	(5.89)	-
(Profit)/Loss on sale of PPE	-	0.89
Interest Income	(73.90)	(45.44)
Operating profit before Working Capital changes	**2,236.54**	**3,381.33**
Working Capital changes:		
(Increase)/ decrease in Inventories	(1,341.07)	(4,084.50)
(Increase)/ decrease in Trade Receivables	(2,015.88)	(2,229.70)
(Increase)/decrease in Short-term Loans, Advances and Deposits	(84.36)	(1,076.65)
(Increase)/decrease in Other Current Assets	(115.96)	112.21
(Increase)/decrease in Other Non Current Assets	(2.69)	0.81
(Decrease)/Increase in Trade Payables	3,142.44	937.34
Increase/ (decrease) in Other Current Liabilities	(333.84)	(104.03)
Increase/(decrease) in Provisions	(252.60)	546.95
Cash generated from /(used in) operations	**1,232.58**	**(2,516.23)**
Direct taxes paid (net of refunds received)	(300.00)	(436.16)
Net cash flow from/(used in) Operating activities	**932.58**	**(2,952.39)**
B. Cash flow from Investing activities		
Purchase of Property, Plant and Equipment	(542.62)	(880.83)
Addition to Intangibles	(157.29)	(729.26)
Investment in Fixed deposits	(46.00)	-
Sale of Property, Plant and Equipment	-	10.40
Interest received	73.90	45.44
Unrealised gain / (loss) from Translation of Foreign subsidiaries	(0.63)	(5.34)
Net cash flow from/(used in) Investing activities	**(672.64)**	**(1,559.59)**
C. Cash flow from Financing activities		
Interest paid	(619.08)	(813.88)
Fresh issue of Equity Shares	-	563.88
Share Premium	-	5,864.35
Issue Expenses	-	(824.23)
Proceeds from Long term Borrowings	300.12	-
Repayment of Long term Borrowings	-	(259.20)
Proceeds from Short term Borrowings	2,452.11	3,521.46
Repayment of Short term Borrowings	-	-
Net cash flow from/(used in) Financing activities	**2,133.15**	**8,052.39**
Net increase in cash and Cash equivalents (A+B+C)	**2,393.09**	**3,540.41**
Cash and Cash equivalents at the beginning of the year	3,939.90	399.49
Cash and Cash equivalents as at the end of the year	**6,332.99**	**3,939.90**
Net difference in cash and cash equivalent	**-**	**-**

For and on behalf of the Board of Directors of
Mahamaya Lifesciences Limited

Krishnamurthy Ganesan
Chairman & Director
DIN - 00270539

Place : Gurugram
Date : 13-11-2026

Notes to Consolidated Financial Results

1. The above Unaudited Consolidated Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors in their Meeting held on November 13, 2026. The Statutory Auditors of the Company have conducted a "Limited Review" of the above Financial Results for the half year ended 30th September, 2026.
2. These financial results have been prepared in accordance with the requirements of Accounting Standards specified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 as amended time to time.
3. The Company has only one reportable Business segment viz. "Agro Chemicals".
4. The demand for Company's products depends on monsoon, pest infestation and crop patterns. Hence there may be variations in the Results from one period to another period.
5. The Company has incorporated a wholly owned subsidiary i.e. Mahamaya Lifesciences (FZE) with 1 equity share of AED 150,000 situated in Sharjah, U.A.E.
6. Total capital contribution to be made in Mahamaya Lifesciences FZE, is AED 150,000/- out of which, the Company has remitted AED 10,000 in 2018 & AED 15,000 in 2019 and is planning to send the balance in FY 26-27 and complete the investment.
7. In the preparation of these Consolidated Financial Statements, investment in Subsidiary has been accounted for in accordance with Accounting Standard (AS) 21, Consolidated Financial Statements.
8. As per MCA notification dated 16th February, 2015 Companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 are exempted from the compulsory requirements of adoption of IND-AS.
9. The Company was listed on the stock exchange on 18th November 2025. In connection with the public issue, equity shares having a face value of Rs. 10 each were issued at a share premium of Rs. 104 per equity share, resulting in an issue price of Rs. 114 per share. The public issue comprised an aggregate of 61,78,800 equity shares, comprising 56,38,800 equity shares issued through a Fresh Issue and 5,40,000 equity shares offered for sale by the Promoters. The proceeds from the Fresh Issue were received by the Company (Rs. 64,28,23,200), whereas the consideration in respect of the Offer for Sale accrued to the Promoters. The public issue was undertaken in accordance with the provisions of the Companies Act, 2013 and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

MAHAMAYA LIFESCIENCES LIMITED

10. The utilisation of IPO proceeds is summarised as under, as certified by the Statutory auditor via certificate dated 3rd November 2026

Sr. No.	Objects of the Issue (as per Prospectus)	Amount Allocated as per Prospectus (₹ crore)	Amount Utilised during the Period (₹ crore)	Unutilised Amount (₹ crore)
1	Purchase of Equipment for Fungicides, Insecticides and Bio fermented formulations	2.98	1.27	1.71
2	Purchase of Equipment for herbicides	0.78	0.22	0.55
3	Funding of capital expenditure towards setting up of new technical manufacturing plant	29.42	3.13	26.28
4	Construction of Warehouse and purchase of machinery	2.53	1.83	0.70
5	Funding of Working capital	18.00	18.00	-
6	General Corporate purpose	8.26	8.26	-
	Total	**61.96**	**32.72**	**29.24**

Out of Rs. 29.24 crore of unutilised funds, Rs. 1.72 crore is the balance in the Monitoring Account and the remaining Rs. 27.52 crore has been deposited in Fixed Deposits, being permitted instruments as per the SEBI ICDR Regulations. The breakup of the same is given below:

Breakup of Fixed Deposits:

Date of Deposit	Name of the Bank	Tenure	Amount Deposited (Rs.)
23-Apr-26	DBS	181 days	3,01,00,000.00
23-Apr-26	DBS	182 days	3,01,00,000.00
22-Jun-26	DBS	122 days	3,00,00,000.00
12-May-26	Yes Bank	181 days	7,50,00,000.00
18-May-26	Axis Bank	185 days	5,00,00,000.00
20-Mar-26	DBS	367 days	1,00,00,000.00
13-Aug-26	HDFC	274 days	3,00,00,000.00
22-Sep-26	HDFC	46 days	1,00,00,000.00
22-Sep-26	HDFC	30 days	1,00,00,000.00
	Total		**27,52,00,000.00**

11. The figures of the corresponding periods have been regrouped/reclassified, wherever necessary to conform to current period classification/presentation.
12. The above unaudited financial results of the Company are available on the Company's website (www.mahamayalifesciences.com) and stock exchanges websites BSE (www.bseindia.com), where the shares of the Company are listed.

MAHAMAYA LIFESCIENCES LIMITED